A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer


Condition: Colon Cancer, Esophageal Carcinoma, Pancreatic Cancer, Prostate Cancer, Gastric Cancer, Hepatic Carcinoma

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03013712

Sponsor: First Affiliated Hospital of Chengdu Medical College

Phase: Phase 1/Phase 2

Eligibility:

  • Age: minimum 18 Years maximum 80 Years
  • Gender: All

Inclusion Criteria:

  • 1. Relapsed or refractory EpCAM positive cancer. 2. KPS > 60. 3. Life expectancy>3 months. 4. Gender unlimited, age from 18 years to 80 years. 5. Assessable lesions with a minimum size of 10mm by CT scan or MRI. 6. Acceptable organ function Hematology:
  • Absolute neutrophil count greater than 800/mm^3 without the support of filgrastim.
  • White blood cell (WBC) (> 2000/mm^3).
  • Platelet count greater than 50,000/mm^3.
  • Hemoglobin greater than 9.0 g/dl. 7. No other serious diseases(autoimmune disease, immunodeficiency etc.). 8. Adequate cardiac function (LVEF ≥ 40%). 9. No other tumors. 10. Patients volunteer to participate in the research.

Exclusion Criteria:

  1. Allergic to cytokines.
  2. Uncontrolled active infection.
  3. Acute or chronic GVHD.
  4. MODS.
  5. Treated with T cell inhibitor.
  6. HIV affected.
  7. Pregnancy.

View trial on ClinicalTrials.gov